AVALO THERAPEUTICS INC - COM NEW (AVTX)

CUSIP: 05338F207

Q1 2023 13F Holders as of 31 Mar 2023

Type / Class
Equity / COM NEW
Total 13F shares
9,130,207
Share change
+3,579,228
Total reported value
$15,977,575
Price per share
$1.75
Number of holders
31
Value change
+$6,149,151
Number of buys
16
Number of sells
11

Quarterly Holders Quick Answers

What is CUSIP 05338F207?
CUSIP 05338F207 identifies AVTX - AVALO THERAPEUTICS INC - COM NEW in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of AVALO THERAPEUTICS INC - COM NEW (AVTX) as of Q1 2023

As of 31 Mar 2023, AVALO THERAPEUTICS INC - COM NEW (AVTX) was held by 31 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 9,130,207 shares. The largest 10 holders included ARMISTICE CAPITAL, LLC, Point72 Asset Management, L.P., VR Adviser, LLC, Nantahala Capital Management, LLC, GREAT POINT PARTNERS LLC, Alyeska Investment Group, L.P., BRAIDWELL LP, VANGUARD GROUP INC, BlackRock Inc., and Maven Securities LTD. This page lists 31 institutional shareholders reporting positions in this security for the Q1 2023 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.